Indeed, we have recently demonstrated that anti-EGFR-ILs-dox can be safely used to deliver cytotoxic molecules to GBM tissue in patients with relapsed GBM (n = 9) harboring an EGFR gene amplification23. This evidence concerns the gene EGFR and glioblastoma.